Research Publications

Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. 

A phase 1 randomized, double-blind, placebo-controlled single ascending dose, multiple dose and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053-1067.

Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, Taylor L, Lauder H, Serpell M.

A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262(1):27-40.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E.

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999-1012.

Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA.

A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.  Br J Pharmacol. 2010;160(3):762-771.

Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ.

The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+signaling and NFAT activation. FASEB J. 2009;23(1):183-193.

Conference Abstracts

Morrison G, Taylor L, Crockett J, Critchley D and Tayo B.

A phase 1 investigation into the potential effects of cannabidiol on CYP3A4 mediated drug-drug interactions in healthy volunteers. Poster 1.297. AES, December2018.

VanLandingham K, Gidal B, Blakey G, Taylor L, Morrison G.

A phase 1 single ascending dose, multiple dose and food effect trial in healthy volunteers. Poster 1.300. AES, December 2018.

Tayo B, Ben-Menachem E, Gunning B, Cabrera CMA, Wray L, Crockett J, Taylor L, Critchley D, Morrison G, Wray L, and Toledo M.

Exploration of plasma protein binding displacement and drug‑drug interactions of valproate in combination with cannabidiol. Poster 1.453. AES, December 2018.

Ben-Menachem E, Gunning B, VanLandingham K,Crockett J, Taylor L, Critchley D, Tayo B, Morrison G, Toledo M.

A phase 2 trial to explore the potential for a pharmacokinetic drug-drug interaction with valproate when in combination with cannabidiol in adult epilepsy patients. Oral Presentation. ECE, August 2018.

Ford-Taylor LA, Chiu S, Renoo J, Pertwee R, Ross R.

Cannabinoids in their acid forms are potent inhibitors of human breast cancer cell viability. Oral Presentation. ICRS, July 2010. Abstract in final program, page 65. Available at:

Ford L, Henstridge C, Deehan M, Pertwee R, Irving A, Ross R.

Preliminary studies on the pharmacology and regulation of the putative cannabinoid receptor GPR55. Poster Presentation. ICRS, June 2007. Abstract in final program, page 101.

Manuscript Mini-Reviews

Abstract-style recommendation of peer-reviewed manuscripts for Faculty of 1000 (F1000) website:

Ramer R, Merkord J, Rohde H and Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 2010;79(7):955-966.

Lau WS, Chen WF, Chan RY, Guo DA, Wong MS. Mitogen-activated protein kinase (MAPK) pathway mediatesthe oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7)cells. Br J Pharmacol. 2009;156(7):1136-1146.